Limited Competition: Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BBAER) Program (UM1), Clinical Trial Optional
The National Human Genome Research Institute (NHGRI) seeks to broaden the types of knowledge, skills, expertise, experience, and perspectives brought to bear in research addressing the ethical, legal and social implications (ELSI) of advances in human genetics or genomics. This Notice of Funding Opportunity (NOFO) solicits UM1 applications from domestic organizations located in the United States and its territories that received less than $30 million per year in total NIH funding for the past three fiscal years. These organizations are underrepresented among those receiving NHGRI funding for ELSI research. The Building Partnerships and Broadening Perspectives to Advance Ethical, Legal, and Social Implications (ELSI) Research (BPAER) Program will support: 1) transdisciplinary ELSI research addressing timely, complex, and understudied topics, 2) the establishment of research teams that include representatives from relevant communities who are affected by and have an interest in the proposed research, 3) research capacity building to develop, conduct and sustain ELSI research, and 4) workforce development opportunities for early career scholars, research team members, and other research project staff. Transdisciplinary ELSI research projects require involvement from two or more fields of knowledge and use of multiple research approaches. Relevant communities must be actively and meaningfully involved on ELSI research teams across all phases of proposed research projects. Research capacity building plans must be informed by a needs assessment. Given the complex structure, a strategic management plan, evaluation plan, and sustainability plan are required to ensure successful completion of the program.
RFA-HG-24-026
Award Ceiling
$850K
Closes
Aug 2, 2026
4d left
A Tribal Self-Governance Negotiation Cooperative Agreement Program
The Tribal Self-Governance Program (TSGP) allows Tribes to negotiate with the Indian Health Service (IHS) to start operating programs, services, functions, and activities (PSFAs). This gives Tribes the authority to manage and tailor health care programs to best suit the needs of their communities. Participating in the TSGP gives your Tribe flexibility to tailor your health care needs by choosing one of three ways to get health care from the Federal Government for your citizens. Tribes can choose to: Get health care services directly from the IHS.Contract with the IHS to administer individual programs and services the IHS would otherwise provide. This is referred to as Title I Self-Determination Contracting.Compact with the IHS to assume control over health care programs the IHS would otherwise provide. This is referred to as Title V Self-Governance Compacting or the TSGP. These options are not exclusive. You may choose to combine options based on your Tribe's needs and circumstances. The purpose of this negotiation cooperative agreement is to help Tribes cover the costs of preparing for and participating in these negotiations.
HHS-2026-IHS-TSGN-0001
Award Ceiling
$84K
Closes
Aug 3, 2026
5d left
National Training Center for Family Planning
The purpose of this funding opportunity is to create a single, coordinated national training center that provides comprehensive TTA to Title X grant recipients and their networks of sub-recipients and service sites. Title X currently operates through a large and diverse network of more than 3,800 service sites who provide Title X services to close to 3 million low-income individuals annually, and these providers rely on consistent, high-quality support to meet statutory and regulatory requirements and OASH and OPA priorities.
PA-FPT-26-001
Award Ceiling
$3.0M
Closes
Aug 5, 2026
7d left
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and career development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs. This Funding Opportunity Announcement (FOA) allows support of [trainees] as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
PAR-24-174
Award Ceiling
—
Closes
Aug 6, 2026
8d left
Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)
This initiative seeks to solicit applications for research projects that address the link between social disconnection including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) and suicide in late-life. Emphasis is placed on research that identifies neurobiological and environmental mechanisms associated with social isolation and loneliness that increase risk for suicidal thoughts and behavior in late-life, that uses an experimental therapeutics approach to identify targets and develop and test interventions to prevent late-life suicide, and that develops new and modifies existing service delivery models to enhance social connection in late-life to prevent suicide.
PAR-25-067
Award Ceiling
—
Closes
Sep 7, 2026
40d left
NIH Director’s Pioneer Award (DP1 Clinical Trial Optional)
The NIH Director"s Pioneer Award supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator"s research program or elsewhere. Applications in all topics relevant to the broad mission of NIH are welcome. Research may involve basic, translational, or clinical research. The NIH Director"s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) program of the NIH Common Fund.
RFA-RM-27-001
Award Ceiling
$700K
Closes
Sep 9, 2026
42d left
NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)
This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a variety of community settings. The purpose of NCORP is to engage cancer patient populations, those at risk of cancer, and organizations in rigorous studies focused on cancer control, prevention, treatment and care delivery.NCORP is a community-based research network that:Designs and conducts clinical trials and other human subject studies for adults and children in cancer control, prevention, screening, and care delivery, as well as quality-of-life studies embedded within treatment trials;Enhances patient and provider access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN);NCORP will support the following components that will be individually awarded through the respective Request for Applications (RFAs) indicated below:NCORP Research Bases (UG1 Clinical Trials Required)(covered by this NOFO);NCORP Community Sites (UG1 Clinical Trials Not Allowed); andNCORP Academic Community Sites (UG1 Clinical Trials Not Allowed).NCORP Research Bases will serve as the program's research hubs and are expected to:Provide an established organizational structure, with scientific and statistical leadership for developing, implementing, and analyzing multi-institutional cancer control, prevention, and care delivery (CCP&CD) clinical research, as well as quality-of-life studies embedded in treatment and imaging studies.Assume responsibility for study operations and data management, including efficient protocol development; compliance with Food and Drug Administration (FDA) and Office of Human Research Protections (OHRP) regulatory and participant protection requirements; auditing; training; quality assurance; and support to Community Sites and Academic Community Sites.Be based at institutions with comprehensive cancer clinical research expertise (e.g., NCI-designated Cancer Center, or healthcare research organization – including NCI's National Clinical Trials Network (NCTN) Group Operations Centers, or a cancer foundation associated with a NCTN Group).
RFA-CA-27-006
Award Ceiling
$74.5M
Closes
Sep 18, 2026
51d left
Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed)
<p>This funding opportunity announcement (FOA) encourages grant applications that support the activities of the National Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for basic and translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers, the resources of which are made available to investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize NHPs in biomedical research and thereby complement and help enable the missions of the NIH Institutes and Centers.</p>
PAR-23-126
Award Ceiling
—
Closes
Sep 25, 2026
58d left
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
This Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) PAR, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplified Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.
PAR-24-280
Award Ceiling
—
Closes
Nov 2, 2026
96d left
Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
This NOFO seeks to advance research and training in high-priority areas of child health by stimulating the use of Environmental Influences on Child Health Outcomes (ECHO) Cohort data by postdoctoral fellows from relevant scientific disciplines. This RFA will provide opportunities for fellows to study child health outcomes through the analysis of ECHO's large longitudinal data sets within the NICHD Data and Specimen Hub (DASH) repository. ECHO's DASH dataset integrates de-identified longitudinal data from more than 71,000 participants across the U.S. Prenatal and child exposure data include physical, chemical, social, behavioral, and biological factors. ECHO's five primary pediatric outcome areas are pre-, peri-, and postnatal outcomes, upper and lower airway, obesity, neurodevelopment, and positive health.
RFA-OD-27-008
Award Ceiling
$1.3M
Closes
Dec 2, 2026
126d left
National Centers for Cryo-electron Tomography (cryoET) (R24 -Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) is for support of National Centers for Cryoelectron Tomography (CryoET) to provide nationwide access to advanced cryoET instrumentation and technical support, and to assist investigators in acquiring the skills needed to perform cryoET studies.
PAR-26-138
Award Ceiling
—
Closes
Jan 26, 2027
181d left
Silvio O. Conte Digestive Diseases Research Core Centers (P30-Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission. DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner. Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of the NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding.
RFA-DK-27-119
Award Ceiling
$750K
Closes
Feb 10, 2027
196d left
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
The Small Business Technology Transfer (STTR) grant program helps United States small business concerns (SBCs) that partner with a nonprofit research institution bring scientific innovations to the marketplace. The STTR program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.
PA-27-102
Award Ceiling
—
Closes
Apr 5, 2027
250d left
Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)
The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to create, provide, and disseminate clinical and translational science training and career support programs that enhance postdoctoral research training of individuals with doctoral degrees (these include, but are not limited to, the following: D.M.D., DC, DO, DVM., OD, DPM, ScD, EngD, DrPH, DNSc, DPT, PharmD, ND [Doctor of Naturopathy], DSW, PsyD, as well as a doctoral degree in nursing research) and help ensure a heterogenous pool of clinical and translational scientists trainees who are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications that improve health and support meaningful translational science research projects that address demonstrable needs among stakeholder communities.
PAR-25-195
Award Ceiling
—
Closes
Sep 28, 2027
426d left
Confirmatory Efficacy Clinical Trials of Non-Pharmacological and Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required). As part of NIMH's clinical trials pipeline NOFOs, this announcement supports confirmatory efficacy testing of non pharmacological therapeutic and preventive interventions for mental disorders in adults and children that address unmet therapeutic needs, and are consistent with the NIMH emphasis on the experimental therapeutics approach. In this approach, clinical trials should be designed to increase knowledge of the relationship between underlying disease processes and the mechanisms of action through which any intervention produces therapeutic change.
PAR-25-179
Award Ceiling
—
Closes
Oct 15, 2027
443d left
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
PAR-25-104
Award Ceiling
—
Closes
Oct 25, 2027
453d left
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
Reissue of PAR-20-118. This Notice of Funding Opportunity (NOFO) encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This NOFO using the U01 mechanism supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion U19 FOA.
PAR-25-352
Award Ceiling
—
Closes
Oct 25, 2027
453d left
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology. Proposed platforms and technologies may have widespread applicability but must be able to improve the outlook for HLBS-related diseases and disorders.
RFA-HL-26-016
Award Ceiling
$350K
Closes
Dec 23, 2027
512d left
Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.
RFA-HL-26-020
Award Ceiling
—
Closes
Dec 23, 2027
512d left
NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years. Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and cost-effectiveness research (Stages IV/V).
PAR-25-188
Award Ceiling
$500K
Closes
Jan 6, 2028
526d left